news_6

CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development...

news_6

IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials

NMPA’s Clearance of CT120 Marks Major Milestone in Treatment for B-Cell Malignancies PLEASANTON, Calif. & NANJING, China & SHANGHAI--(BUSINESS WIRE)--#Biopharmaceutical--IASO...

news_6

Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19

Arcturus will receive $40 million upfront payment and potential royalties based on vaccines produced SAN DIEGO--(BUSINESS WIRE)--$ARCT #ClinicalTrial--Arcturus Therapeutics Holdings...

news_6

MUFG Bank, Ltd. Announces Consolidated Summary Report of Mitsubishi UFJ Financial Group, Inc. Under Japanese GAAP for the Three Months Ended June 30, 2021

Consolidated Summary Report for the three months ended June 30, 2021 TOKYO--(BUSINESS WIRE)--MUFG Bank, Ltd.: Company name: Mitsubishi UFJ Financial...